TP53 and colorectal carcinoma: Despite the prevalence of TP53 mutations in cancer, many retrospective studies have failed to identify associations between TP53 abnormalities (e.g., mutations, amplifications) and clinicopathologic phenotypes5, and the lack of well-established clinical significance between patient outcomes and TP53 status has become one of the most controversial topics in cancer research, including GC and colorectal cancer (CRC)1, 5, 6, 7.